Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) have announced a partnership worth up to $7.9 million to support the development of IPH6501 in follicular lymphoma. The agreement includes a $3 million upfront investment from IFLI in Innate shares at €1.56 per share, representing 2.26% of Innate's share capital, with potential additional investments of up to $4.9 million tied to milestone achievements.
The collaboration will expand Innate's ongoing Phase 1/2 trial of IPH6501, an anti-CD20 ANKET®, to include patients with relapsed/refractory follicular lymphoma. The trial is currently investigating the safety, tolerability, and preliminary antineoplastic activity in patients with CD20-expressing Non-Hodgkin Lymphoma.
Innate Pharma e l'Istituto per l'Innovazione del Linfoma Follicolare (IFLI) hanno annunciato una partnership del valore di fino a 7,9 milioni di dollari per sostenere lo sviluppo di IPH6501 nel linfoma follicolare. L'accordo prevede un investimento iniziale di 3 milioni di dollari da parte di IFLI in azioni Innate a 1,56 € per azione, rappresentando il 2,26% del capitale azionario di Innate, con investimenti aggiuntivi potenziali fino a 4,9 milioni di dollari legati al raggiungimento di traguardi.
La collaborazione espanderà la sperimentazione in corso di Fase 1/2 di IPH6501, un anti-CD20 ANKET®, per includere pazienti con linfoma follicolare recidivante/refrattario. La sperimentazione sta attualmente investigando la sicurezza, la tollerabilità e l'attività antineoplastica preliminare in pazienti con linfoma non-Hodgkin esprimente CD20.
Innate Pharma y el Instituto para la Innovación del Linfoma Follicular (IFLI) han anunciado una asociación por valor de hasta 7,9 millones de dólares para apoyar el desarrollo de IPH6501 en linfoma follicular. El acuerdo incluye una inversión inicial de 3 millones de dólares por parte de IFLI en acciones de Innate a 1,56 € por acción, representando el 2,26% del capital social de Innate, con inversiones adicionales potenciales de hasta 4,9 millones de dólares vinculadas a logros de hitos.
La colaboración ampliará el ensayo en curso de Fase 1/2 de IPH6501, un anti-CD20 ANKET®, para incluir pacientes con linfoma follicular en recaída/refractario. El ensayo está investigando actualmente la seguridad, la tolerabilidad y la actividad antineoplásica preliminar en pacientes con linfoma no Hodgkin que expresan CD20.
Innate Pharma와 모낭 림프종 혁신 연구소 (IFLI)는 모낭 림프종에서 IPH6501의 개발을 지원하기 위해 최대 790만 달러 규모의 파트너십을 발표했습니다. 이 계약에는 IFLI가 Innate의 주식에 대해 주당 1.56 유로로 300만 달러를 선투자하는 것이 포함되어 있으며, 이는 Innate의 자본금의 2.26%에 해당하며, 이정표 달성과 관련하여 최대 490만 달러의 추가 투자가 있을 수 있습니다.
이번 협업은 재발/불응성 모낭 림프종 환자를 포함하도록 IPH6501의 진행 중인 1/2상 임상 시험을 확장할 것입니다. 현재 이 임상 시험은 CD20을 발현하는 비호지킨 림프종 환자에서의 안전성, 내약성 및 초기 항신생물 활성에 대해 조사하고 있습니다.
Innate Pharma et l'Institut pour l'Innovation du Lymphome Folliculaire (IFLI) ont annoncé un partenariat d'une valeur allant jusqu'à 7,9 millions de dollars pour soutenir le développement de IPH6501 dans le lymphome folliculaire. L'accord comprend un investissement initial de 3 millions de dollars de la part de l'IFLI dans des actions Innate à 1,56 € l'action, représentant 2,26 % du capital social d'Innate, avec des investissements additionnels potentiels allant jusqu'à 4,9 millions de dollars liés à l'atteinte de jalons.
La collaboration élargira l'essai de Phase 1/2 en cours d'IPH6501, un anti-CD20 ANKET®, pour inclure des patients avec un lymphome folliculaire en rechute/réfractaire. L'essai enquête actuellement sur la sécurité, la tolérabilité et l'activité antinéoplasique préliminaire chez les patients atteints de lymphome non hodgkinien exprimant le CD20.
Innate Pharma und das Institut für Innovation im follikulären Lymphom (IFLI) haben eine Partnerschaft im Wert von bis zu 7,9 Millionen Dollar zur Unterstützung der Entwicklung von IPH6501 bei follikulärem Lymphom angekündigt. Die Vereinbarung umfasst eine Vorauszahlung von 3 Millionen Dollar von IFLI in Innate-Aktien zu 1,56 € pro Aktie, was 2,26% des Grundkapitals von Innate entspricht, sowie potenzielle zusätzliche Investitionen von bis zu 4,9 Millionen Dollar, die an den Erreichungsgrad bestimmter Meilensteine gebunden sind.
Die Zusammenarbeit wird die laufende Phase 1/2-Studie von IPH6501, einem anti-CD20 ANKET®, erweitern, um Patienten mit rezidivierendem/refraktärem follikulärem Lymphom einzubeziehen. Die Studie untersucht derzeit die Sicherheit, Verträglichkeit und erste antitumorale Aktivität bei Patienten mit CD20-exprimierendem Non-Hodgkin-Lymphom.
- Secured up to $7.9M in funding from IFLI
- Immediate $3M upfront investment received
- Additional $4.9M potential milestone-based funding
- Expansion of ongoing Phase 1/2 trial to include follicular lymphoma patients
- 2.26% shareholder dilution from initial investment
- Future potential share dilution from milestone-based investments
Insights
The
The partnership with IFLI, a specialized institute, adds credibility to Innate's development program and could accelerate patient recruitment. The milestone-based structure aligns incentives and provides additional funding flexibility while maintaining upside potential for both parties. For a company with a market cap of
The expansion of IPH6501's Phase 1/2 trial to include R/R follicular lymphoma patients is strategically significant. The ANKET® platform targeting CD20+ represents an innovative approach in treating non-Hodgkin lymphoma, particularly for relapsed/refractory cases where treatment options are The study's focus on both safety and preliminary antineoplastic activity could provide valuable efficacy signals in this difficult-to-treat patient population.
IFLI's involvement brings specialized expertise in follicular lymphoma research, potentially enhancing trial design and execution. Their willingness to provide milestone-based funding suggests confidence in the preliminary data and development strategy. The collaboration could accelerate the development timeline and increase the probability of successful outcomes in the follicular lymphoma indication.
-
Innate will receive
3m USD upfront plus up to4.9m USD in conditional tranched investments from The Institute for Follicular Lymphoma Innovation (IFLI) - Patients with R/R Follicular Lymphoma will be included in the ongoing Phase 1/2 trial investigating IPH6501 in patients with R/R CD20+ Non-Hodgkin Lymphoma
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), together with the Institute for Follicular Lymphoma (IFLI) today announced that they have entered into an agreement to clinically study the potential of IPH6501, Innate's anti-CD20 ANKET® in follicular lymphoma (FL).
Innate’s ongoing Phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501 in patients with relapsed and/or refractory CD20-expressing Non-Hodgkin Lymphoma will also include patients with relapsed / refractory (R/R) FL.
To support the Phase 1/2 trial and inclusion of FL patients, IFLI will initially invest
IFLI may also invest up to an additional
“At Innate Pharma, we are deeply committed to advancing innovative research and development to improve outcomes for patients with non-Hodgkin lymphoma and this agreement with the Institute for Follicular Lymphoma Innovation will contribute to our mission to bring forward therapeutic options that address critical needs and enhance the quality of life for those affected by this challenging disease,” said Dr Sonia Quaratino, Chief Medical Officer of Innate Pharma.
“IFLI believes IPH6501 holds great promise for improving patient outcomes in non-Hodgkin lymphomas including follicular lymphoma,” said Dr. Michel Azoulay, Chief Medical Officer of IFLI. “We are delighted to support Innate and the investigation of IPH6501 in FL patients and, upon milestone achievement, to continue to support future clinical development of IPH6501 in FL. This collaboration provides a model for how IFLI’s philanthropic investments can catalyze FL development.”
You can find more details on the transaction in the attached PDF.
About The Institute for Follicular Lymphoma Innovation
The Institute for Follicular Lymphoma Innovation (IFLI) is a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL). IFLI supports cutting-edge research and technology to lead to the development and commercialization of novel therapeutics and/or biomarkers for the treatment of FL, and to understand the biology of FL. The foundation deploys its budget across grants, project-based partnerships, and venture philanthropic investments to achieve its innovation goals. IFLI promotes collaboration and works to enable data sharing and the exchange of knowledge and expertise among researchers and institutions advancing FL research. Learn more at www.i-fli.org.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET® multi-specific NK cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in
Learn more about Innate Pharma at www.innate-pharma.com and follow us on Twitter and LinkedIn.
Information about Innate Pharma shares
ISIN code
|
FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “expect” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205918622/en/
For additional information, please contact:
Investors
Innate Pharma
Henry Wheeler
Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
For Innate:
NewCap
Arthur Rouillé
Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
For IFLI:
Laura DiCaprio
McDougall Communications
laura@mcdougallpr.com
+1 (585) 434-2153
Source: Innate Pharma SA
FAQ
What is the total investment IFLI is making in Innate Pharma (IPHA)?
What is the share price for IFLI's initial investment in Innate Pharma (IPHA)?
What is the purpose of IFLI's investment in Innate Pharma (IPHA)?
